Čájehuvvojit 1 - 20 oktiibuot 22 bohtosis ohcui ', ohcanáigi: 0,03s Aiddostahte ozu
  1. 1

    The emergence of the SARS-CoV-2 Omicron variant

    Almmustuhtton 2022
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
  2. 2

    How is Omicron different?

    Almmustuhtton 2022
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
  3. 3

    SARS-CoV-2 variants implications for immunity and vaccine development /

    Almmustuhtton 2021
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
  4. 4

    SARS-CoV-2 evolution emergence of the "Californian" and "Indian" variants /

    Almmustuhtton 2021
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
  5. 5

    SARS-CoV-2 evolution within and between individuals

    Almmustuhtton 2021
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
  6. 6

    Identifying SARS-CoV-2 proteases

    Almmustuhtton 2021
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
  7. 7

    Genetic surveillance and the emergence of SARS-CoV-2 variants

    Almmustuhtton 2021
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
  8. 8

    The role of short linear motifs (SLiMs) in SARS-CoV-2 entry into human cells

    Almmustuhtton 2021
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
  9. 9

    The role of Neuropilin-1 as a SARS-CoV-2-specific endocytosis potentiator

    Almmustuhtton 2021
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
  10. 10

    COVID-19 epidemiology and variants new challenges and future of the pandemic /

    Almmustuhtton 2021
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
  11. 11

    Interspecies transmission of SARS-CoV-2

    Almmustuhtton 2021
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
  12. 12

    SARS-CoV-2 mutations phenotypes and implications for vaccine development /

    Almmustuhtton 2021
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
  13. 13

    The evolutionary origin of SARS-CoV-2

    Almmustuhtton 2020
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
  14. 14

    An FDA approved salivary test for SARS-CoV-2 infection

    Almmustuhtton 2020
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
  15. 15

    A novel AIOD-CRISPR system for diagnosis of SARS-COV-2

    Almmustuhtton 2020
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
  16. 16

    SARS-COV-2 what we need to know and possible future therapies /

    Almmustuhtton 2020
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
  17. 17

    The COVID-19 coronavirus outbreak March 2020 update /

    Almmustuhtton 2020
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
  18. 18

    SARS-COV-2 vaccine current biological targets and considerations /

    Almmustuhtton 2020
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
  19. 19

    The current understanding of the biology of the SARS-COV-2 virus

    Almmustuhtton 2020
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
  20. 20

    The paediatric response to the SARS-COV-2 virus and what we can learn from it

    Almmustuhtton 2020
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna